Treatment with low-dose tyrosine kinase inhibitors due to significant haematologic toxicity in patients with CML with prolonged treatment failure prevents haematologic progression

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F24%3A00013687" target="_blank" >RIV/00023736:_____/24:00013687 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/61989592:15110/24:73626354 RIV/00098892:_____/24:10158761

Výsledek na webu

<a href="https://doi.org/10.1016/j.htct.2024.03.010" target="_blank" >https://doi.org/10.1016/j.htct.2024.03.010</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.htct.2024.03.010" target="_blank" >10.1016/j.htct.2024.03.010</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Treatment with low-dose tyrosine kinase inhibitors due to significant haematologic toxicity in patients with CML with prolonged treatment failure prevents haematologic progression

Popis výsledku v původním jazyce

A lower dosage of tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukaemia (CML) has shown efficacy in managing short-term toxicity and maintaining a deep molecular response in patients who fail to achieve treatment-free remission. From over 700 patients with CML who were treated at two centres over the last three decades, this retrospective study identified eight patients characterised by long-term treatment failure and simultaneous prolonged significant haematologic toxicity that prevented the use of the standard tyrosine kinase inhibitor dosage. It is important not to stop treatment with tyrosine kinase inhibitors at a low personalised dosage in CML patients with prolonged significant haematologic toxicity despite long-term treatment failure.

Název v anglickém jazyce

Treatment with low-dose tyrosine kinase inhibitors due to significant haematologic toxicity in patients with CML with prolonged treatment failure prevents haematologic progression

Popis výsledku anglicky

A lower dosage of tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukaemia (CML) has shown efficacy in managing short-term toxicity and maintaining a deep molecular response in patients who fail to achieve treatment-free remission. From over 700 patients with CML who were treated at two centres over the last three decades, this retrospective study identified eight patients characterised by long-term treatment failure and simultaneous prolonged significant haematologic toxicity that prevented the use of the standard tyrosine kinase inhibitor dosage. It is important not to stop treatment with tyrosine kinase inhibitors at a low personalised dosage in CML patients with prolonged significant haematologic toxicity despite long-term treatment failure.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Hematology transfusion and cell therapy

ISSN

2531-1379

e-ISSN

—

Svazek periodika

46

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

BR - Brazilská federativní republika

Počet stran výsledku

11

Strana od-do

"S171"-"S181"

Kód UT WoS článku

001392017600001

EID výsledku v databázi Scopus

2-s2.0-85199961204